Guest Editors
Benjamin Haley, PhD, University of Montreal, Canada
Francisco J. Sánchez-Rivera, PhD, Koch Institute for Integrative Cancer Research at MIT, USA
Submission Status: Open | Submission Deadline: 14 November 2025
Genome editing in human health, disease, and therapeutics
About the Collection
Genome Medicine is pleased to present the Collection, “Genome editing in human health, disease, and therapeutics”. Genome editing has revolutionized our understanding of gene function, regulation, and how we approach treating genetic disorders and diseases. Advancements in the CRISPR toolkit and adaptations such as base, prime, and epigenome editing have had a profound impact in the field of precision editing, from target discovery to gene therapy. The development of novel technologies that allow for the correction of disease-causing mutations and the introduction of therapeutic changes will unlock new avenues for precision therapeutics, and potentially improve treatment outcomes for patients with conditions such as monogenic disorders, infectious diseases, and cancer.
In this special issue, guest edited by Dr Benjamin Haley and Dr Francisco Sánchez-Rivera, we aim to highlight advances in genome editing approaches and applications in human health, disease, and therapeutics. We are inviting the submission of Research, Method, Software, and Guideline manuscripts with significant translational or clinical impact, in all areas of human disease, including:
- Genome, epigenome and transcriptome editing
- Target identification and drug discovery using genome editing technologies
- Synthetic biology and genome writing
- Preclinical in vivo and ex vivo applications
- Viral and non-viral delivery of genome editors
- Precision gene and cell therapies
- Genome editing safety and off-target effects
- Ethical and scientific considerations of editing heritable genetic material
- Sequencing and computational approaches in genome editing
We encourage work that fosters academic-industry partnerships and collaboration among scientists from multi-disciplinary fields.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer-review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Image credit: © catalin / stock.adobe.com
Meet the Guest Editors
Back to topBenjamin Haley, PhD, University of Montreal, Canada
Dr Haley earned his PhD in Biomedical Sciences from UMass Medical School, during which time he established several key biochemical steps in the RNA interference pathway. Afterwards, he received a fellowship from the American Cancer Society to perform postdoctoral research at UC Berkeley, where he identified unique small RNAs and transcriptional processes and developed enhanced gene silencing technologies in a variety of model organisms. Prior to joining the Université de Montréal as a Full Professor (Professeur titulaire) within the Department of Ophthalmology and as the Fonds de recherche du Québec (FRQ) Chair in Genomic Engineering, Ben spent more than 13 years as a group leader (Distinguished Scientist) at Genentech, Inc, where his teams created and applied a range of molecular genetic technologies for basic and clinical research programs across the field of Oncology, Immunology, Neurobiology, Cancer Immunology, Infectious Disease, and Biologics Manufacturing.
Francisco J. Sánchez-Rivera, PhD, Koch Institute for Integrative Cancer Research at MIT, USA
Dr Sánchez-Rivera obtained his PhD in Biology from MIT. Working with Tyler Jacks, he was among the first to use CRISPR to interrogate cancer drivers in vivo, and to identify genotype-specific dependencies in lung adenocarcinoma. As a HHMI Hanna Gray Fellow with Scott W. Lowe at MSKCC, he developed and applied precision genome editing methods to engineer and study specific mutations in cells and tissues of living animals, as well as new approaches to investigate these using single cell genomics. He is currently the Eisen & Chang Career Development Assistant Professor in the Department of Biology at MIT, an Intramural Member of the Koch Institute for Integrative Cancer Research, and an Associate Member of the Broad Institute Cancer Program. The goal of his lab is to understand the links between genetics and cancer to find more precise ways to intercept and treat this disease. To do so, they develop and integrate genome editing and computational methods with mouse models and high-throughput ‘omics’ approaches to obtain comprehensive biological pictures of disease initiation and evolution. Using these approaches, they hope to elucidate and characterize genetic and non-genetic mechanisms regulating tumorigenesis and disease progression, as well as gain an understanding of how these can be modulated to treat cancer and other diseases.
There are currently no articles in this collection.
Submission Guidelines
Back to topThis Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Genome editing in human health, disease, and therapeutics" from the dropdown menu.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.